459 related articles for article (PubMed ID: 28579164)
41. Peri-strut low intensity areas and in-scaffold neointima growth after bioresorbable scaffold implantation in STEMI. A serial optical coherence tomography study.
Ochijewicz D; Tomaniak M; Kołtowski L; Rdzanek A; Pietrasik A; Proniewska K; Partyka L; Dijsktra J; Huczek Z; Filipiak K; Opolski G; Kochman J
Int J Cardiol; 2020 Aug; 312():27-32. PubMed ID: 32315682
[TBL] [Abstract][Full Text] [Related]
42. The relationship between post-stent strut apposition and follow-up strut coverage assessed by a contour plot optical coherence tomography analysis.
Kim JS; Ha J; Kim BK; Shin DH; Ko YG; Choi D; Jang Y; Hong MK
JACC Cardiovasc Interv; 2014 Jun; 7(6):641-51. PubMed ID: 24835329
[TBL] [Abstract][Full Text] [Related]
43. Effect of non-compliant balloon postdilatation on magnesium-based bioresorbable vascular scaffolds.
Blachutzik F; Achenbach S; Tröbs M; Marwan M; Weissner M; Nef H; Schlundt C
Catheter Cardiovasc Interv; 2019 Feb; 93(2):202-207. PubMed ID: 30196573
[TBL] [Abstract][Full Text] [Related]
44. Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound.
Kawamoto H; Ruparelia N; Latib A; Miyazaki T; Sato K; Tanaka A; Naganuma T; Sticchi A; Chieffo A; Carlino M; Montorfano M; Colombo A
Catheter Cardiovasc Interv; 2017 Apr; 89(5):789-797. PubMed ID: 27545845
[TBL] [Abstract][Full Text] [Related]
45. OCT-assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for poly-l-lactic acid bioresorbable vascular scaffolds.
Blachutzik F; Achenbach S; Marwan M; Tröbs M; Boeder N; Doerr O; Weissner M; Bauer T; Nef H; Hamm C; Schlundt C
Catheter Cardiovasc Interv; 2019 Dec; 94(7):928-935. PubMed ID: 30945432
[TBL] [Abstract][Full Text] [Related]
46. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study.
Gomez-Lara J; Diletti R; Brugaletta S; Onuma Y; Farooq V; Thuesen L; McClean D; Koolen J; Ormiston JA; Windecker S; Whitbourn R; Dudek D; Dorange C; Veldhof S; Rapoza R; Regar E; Garcia-Garcia HM; Serruys PW
EuroIntervention; 2012 Jun; 8(2):214-24. PubMed ID: 22030265
[TBL] [Abstract][Full Text] [Related]
47. Hemodynamic analysis of a novel bioresorbable scaffold in porcine coronary artery model.
Tenekecioglu E; Torii R; Bourantas CV; Cavalcante R; Sotomi Y; Zeng Y; Collet C; Crake T; Abizaid A; Onuma Y; Su S; Santoso T; Serruys PW
Catheter Cardiovasc Interv; 2018 May; 91(6):1084-1091. PubMed ID: 28843033
[TBL] [Abstract][Full Text] [Related]
48. Minimal Acute Recoil Following Bioresorbable Scaffold Implantation in Fibrocalcific Lesion Detected by Optical Frequency-Domain Imaging.
Kawamoto H; Ruparelia N; Tanaka A; Latib A; Colombo A
J Invasive Cardiol; 2016 Mar; 28(3):E34-6. PubMed ID: 26945257
[TBL] [Abstract][Full Text] [Related]
49. Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography.
Boeder NF; Dörr O; Gaderer R; Blachutzik F; Achenbach S; Elsässer A; Hamm C; Nef HM
Postepy Kardiol Interwencyjnej; 2021 Sep; 17(3):272-280. PubMed ID: 34819963
[TBL] [Abstract][Full Text] [Related]
50. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
[TBL] [Abstract][Full Text] [Related]
51. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
[TBL] [Abstract][Full Text] [Related]
52. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
[TBL] [Abstract][Full Text] [Related]
53. Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent.
Schneider VS; Skurk C; Riedel M; Abdelwahed YS; Landmesser U; Leistner DM
Clin Res Cardiol; 2017 Jul; 106(7):557-559. PubMed ID: 28374059
[No Abstract] [Full Text] [Related]
54. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Stent Expansion Guided by Optical Coherence Tomography Versus Intravascular Ultrasound: The ILUMIEN II Study (Observational Study of Optical Coherence Tomography [OCT] in Patients Undergoing Fractional Flow Reserve [FFR] and Percutaneous Coronary Intervention).
Maehara A; Ben-Yehuda O; Ali Z; Wijns W; Bezerra HG; Shite J; Généreux P; Nichols M; Jenkins P; Witzenbichler B; Mintz GS; Stone GW
JACC Cardiovasc Interv; 2015 Nov; 8(13):1704-14. PubMed ID: 26585621
[TBL] [Abstract][Full Text] [Related]
56. One Year of OCT Follow-Up After Implantation of Three Different BRS in the Same Coronary Artery.
Franzè A; Cerrato E; Rolfo C; Quadri G; Tomassini F; Varbella F
Cardiovasc Revasc Med; 2020 Nov; 21(11S):121-122. PubMed ID: 32513605
[No Abstract] [Full Text] [Related]
57. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
58. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
[TBL] [Abstract][Full Text] [Related]
59. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation.
Brown AJ; McCormick LM; Braganza DM; Bennett MR; Hoole SP; West NE
Catheter Cardiovasc Interv; 2014 Jul; 84(1):37-45. PubMed ID: 24403223
[TBL] [Abstract][Full Text] [Related]
60. Long-term invasive follow-up of bioresorbable vascular scaffold: Optical Coherence Tomography assessment of jailed side branches.
Paradies V; Smits PC; Vachojannis GJ; Royaards KJ; Wassing J; van der Ent M
Cardiovasc Revasc Med; 2018 Apr; 19(3 Pt A):279-285. PubMed ID: 29066339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
